All In Biotech

Drug Trial Radar · NCT00151892

Efficacy and Safety of SPD476 in Maintaining Remission in Patients With Ulcerative Colitis

A Phase III, Randomized Multi-centre, Double-blind, Parallel Group, Active Comparator Study to Compare the Efficacy and Safety of SPD476 (Mesalazine)2.4g/Day Once Daily With Asacol 1.6g/Day Twice Daily in the Maintenance of Remission in Patients With Ulcerative Colitis

Last checked: Nov 19, 2026Latest source record: Jun 14, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 829 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

829

Actual

Start

Apr 8, 2005

Primary completion

Sep 7, 2009

Study completion Sep 7, 2009

Sponsor

Lead sponsor
ShireTakeda (TAK)
Sponsor type
Industry
First posted
Sep 9, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Ulcerative colitis is a disease of the large bowel (colon) and rectum in which the lining of the bowel becomes red and swollen. Over time, patients with this disease may experience acute episodes of diarrhea, rectal bleeding and abdominal pain followed by periods of time without disease symptoms. 5-ASA drugs are a standard treatment for ulcerative colitis. Mesalazine is an experimental drug designed to gradually release 5-ASA into the areas of large bowel associated with ulcerative colitis. This study will test the safety and efficacy of mesalazine in keeping ulcerative colitis in remission.

Conditions

  • Ulcerative Colitis

Interventions

  • SPD476Drug

    2.4 g/day Once Daily (QD)

  • AsacolDrug

    1.6g/day administered 800 mg Twice Daily (BID)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Endoscopic Remission of Ulcerative Colitis (UC) at 6 MonthsTime frame: 6 Months

Locations

142 sites in 28 countries. Site status is shown where the registry gives one.

  • Birmingham Gastroenterology Associates

    Birmingham, Alabama

  • Connecticut Gastroenterology Institute

    Bristol, Connecticut

  • Washington Gastroenterology

    Washington D.C., District of Columbia

  • Southern Clinical Research Consultants

    Hollywood, Florida

  • Boorland-Groover Clinic

    Jacksonville, Florida

  • United Medical Research

    New Smyrna Beach, Florida

  • Atlanta Gastroenterology Associates

    Atlanta, Georgia

  • Midwest Clinical Research Center

    Moline, Illinois

  • Gastrointestinal Clinic of Quad Cities

    Davenport, Iowa

  • Drug Research Services, Inc.

    Metairie, Louisiana

  • Mayo Clinic

    Rochester, Minnesota

  • Center for Digestive and Liver Diseases, Inc

    Mexico, Missouri

  • New York Center for Clinical Research

    Lake Success, New York

  • ClinSearch

    Chattanooga, Tennessee

  • S D Khan

    Houston, Texas

  • Centro Integral De Gastroenterologia

    Ciudad de Buenos Aires, Argentina

  • Hospital Italiano de Mendoza, FINAMED SA

    Mendoza, Argentina

  • Hospital Italiano de Buenos Aires

    Capital Federal, Buenos Aires, Argentina

  • Bankstown-Lidcombe Hospital

    Bankstown, New South Wales, Australia

  • Concord Hospital

    Concord, New South Wales, Australia

  • Royal Adelaide Hospital

    Adelaide, South Australia, Australia

  • Eastern Health Hospital

    Box Hill, Victoria, Australia

  • St Vincent's Hospital

    Fitzroy, Victoria, Australia

  • Fremantle Hospital

    Fremantle, Western Australia, Australia

  • Imelda General Hospital

    Bonheiden, Belgium

  • Ziekenhuis Oost Limburg

    Genk, Belgium

  • Heilig Hart ziekenhuis vzw Roeselare-Menen

    Roeselare, Belgium

  • Unigastro

    Castelo, Brazil

  • Hospital de Clinicas

    Porto Alegre, Brazil

  • Universidade Federal do Rio de Janeiro

    Rio de Janeiro, Brazil

  • Universidade Federal da Bahia - Hospital

    Salvador, Brazil

  • Hospital Sao Paulo

    São Paulo, Brazil

  • Hospital Israelita Albert Einstein

    São Paulo, Brazil

  • GI Research

    Edmonton, Canada

  • University of Calgary

    Calgary, Alberta, Canada

  • Toronto Digestive Disease Associates, Inc.

    Toronto, Ontario, Canada

  • Hopital Maisonneuve-Rosemont

    Montreal, Quebec, Canada

  • Hópital Hótel-Dieu de Quebec

    Québec, Quebec, Canada

  • Hospital del Salvador

    Santiago, Chile

  • Clinica Las Condes

    Santiago, Chile

Showing 40 of 142 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.